H.C. Wainwright analyst Matthew Caufield downgraded Aldeyra (ALDX) to Neutral from Buy with a price target of $2, down from $10, after the company received a complete response letter from the FDA related to reproxalap for the topical treatment of the signs and symptoms of dry eye disease. The firm reduced its probability of success for reproxalap from 75% to 40% and downgraded Aldeyra.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALDX:
- Morning News Wrap-Up 3/17/26: Today’s Biggest Stock Market Stories!
- FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy
- How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?
- FDA Issues Second Complete Response Letter for Reproxalap
- Aldeyra options imply 10.9% move in share price post-earnings